Artrox (chondroitin sulfate sodium) solution for injections 100 mg/ml. 2 ml. №10vial

active substance:   chondroitin sodium sulfate;

1 bottle (2 ml of medicine) contains chondroitin sodium sulfate 200 mg;

auxiliary substances : benzyl alcohol, water for injections.

Solution for injections.

Main physicochemical properties: transparent colorless or slightly yellowish solution.

Drugs affecting the musculoskeletal system. Chondroitin sulfate. ATX code M01A X25.

The main active substances of the medicinal product are sodium salts of chondroitin sulfate A and C (average molecular weight of 11,000 daltons). Chondroitin sulfate is a high molecular weight mucopolysaccharide. It is the main component of proteoglycans, which together with collagen fibers form the cartilage matrix.

The drug inhibits the degeneration process and stimulates the regeneration of cartilage tissue, has a chondroprotective, anti-inflammatory, analgesic effect. Replaces chondroitin sulfate of articular cartilage, catabolized by a pathological process. Suppresses the activity of enzymes that cause degradation of articular cartilage: inhibits metalloproteinases, namely leukocyte elastase. Reduces the activity of hyaluronidase. Partially blocks the emission of free oxygen radicals; helps to block chemotaxis, antigenic determinants. Stimulates the production of proteoglycans by chondrocytes. Affects phosphorus-calcium exchange in cartilage tissue. Makes it possible to restore the mechanical and elastic integrity of the cartilage matrix.

The use of the drug helps to restore the joint bag and cartilaginous surfaces of the joints, prevents compression of the connective tissue, acts as a lubricant for the joint surfaces, normalizes the production of joint fluid, improves the mobility of the joints, and helps reduce the intensity of pain.

Chondroitin sulfate slows down the resorption of bone tissue and reduces calcium loss, accelerates bone tissue recovery processes.

After intramuscular administration of chondroitin sulfate penetrates into the synovial fluid. The maximum concentration in the synovial fluid is reached 4-5 hours after the injection. It is excreted from the body within 24 hours. It is eliminated mainly by the kidneys.

Degenerative-dystrophic diseases of the joints and spine (primary arthrosis, intervertebral osteochondrosis, osteoarthrosis), osteoporosis, periodontopathy, fractures (to accelerate the formation of bone calluses), as well as for the purpose of treating the consequences of operations on the joints.

Increased individual sensitivity to any of the components of the medicinal product, tendency to bleeding, thrombophlebitis, kidney failure, insufficiency of liver function in the stage of decompensation, pregnancy, breastfeeding period, children’s age (up to 18 years).

With caution: with blood coagulation disorders; with diabetes; patients with increased body weight; patients following a low-salt diet; with impaired kidney function; women planning pregnancy.